12:07 PM EST - Bausch Health Companies Inc. : And its gastroenterology (GI) business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today released a report of survey results that offers perspectives from U.S. adults living with irritable bowel syndrome (IBS) during the COVID-19 pandemic. Bausch Health Companies Inc.
shares T.BHC are trading up $0.17 at $38.07.
